Latest on Pharmaceutical Industry


Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. The drug, sarilumab, wh..Read More...

Novo Nordisk looks to expand Latin American obesity business

Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday. Nov..Read More...



3rd Pharmaceutical Packaging & Labeling Forum

Hallam Conference Centre,
United States,


8th International Conference on Proteomics and Bioinformatics

Hyatt Regency Osaka,
Conferenceseries Ltd

Press Releases

FDA approves first drug to specifically treat giant cell arteritis

The US Food and Drug Administration today expanded the approved use of subcutaneous Actemra tocilizumab to treat adults with giant cell arteritis This new indication provides the first FDAapproved therapy specific to thi.. Read More...

Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

Windtree Therapeutics Inc a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases today announced that it has been awarded 09 million under a previously announced Phase.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics